在绝经前乳腺癌中基因表达特征的塔莫西芬预测值:来自随机SBII:2试验的数据
Christine Lundgren1,2,3, Julia Tutzauer4, Sarah E Church5
1Department of Oncology, Region Jönköping County, Jönköping, Sweden. christine.lundgren@rjl.se.
Breast cancer research : BCR
|September 29, 2023
概括
基因表达特征预测了在绝经前乳腺癌中他莫西芬治疗的有效性. FOXA1表达是一种有前途的生物标志物,而其他标志物,如ESR1和乳腺细胞,则具有预后价值.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 药物基因组学 药物基因组学
背景情况:
- 基因表达 (GEX) 签名为乳腺癌提供预后见解.
- 对于他莫西芬治疗的GEX特征的预测价值在很大程度上仍未被探索.
- 这项研究研究了GEX特征在绝经前早期乳腺癌患者的预测和预后作用.
研究的目的:
- 评估各种基因表达特征的塔莫西芬预测值.
- 评估这些特征在患有早期乳腺癌的绝经前妇女的预后影响.
- 确定潜在的生物标志物,以指导他莫西芬治疗决策.
主要方法:
- 从437名绝经前妇女的瘤组织中提取的RNA,随机分配给他莫西芬或没有全身治疗.
- 使用NanoString乳腺癌360TM面板进行的基因表达特征分析.
- 卡普兰-梅尔估计和考克斯回归分析了GEX特征,无复发间隔 (RFi) 和整体存活率 (OS) 之间的关联,并进行了错误发现率调整.
主要成果:
- 在ER+/HER2-瘤中,低FOXA1表达预测了对RFi和OS的提升.
- 高ESR1,巨细胞和PGR表达与分子亚型的10年RFi和OS改进相关.
- 高BC扩散和低氧得分与RFi和OS的较差结果有关.
结论:
- 福克斯A1表达是一种潜在的预测生物标志物,用于特莫西芬在ER+/HER2-绝经前乳腺癌中的疗效.
- 包括BC增殖,缺氧,巨细胞,AR,ESR1和PGR在内的签名显示出预后价值.
- 这些发现表明,GEX签名可以在这个患者群体中为治疗策略和预后评估提供信息.
相关概念视频
Cancer-Critical Genes II: Tumor Suppressor Genes
7.5K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.5K
Cancer Survival Analysis
380
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
380


